The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, raised $81 million by offering 6.2 million shares at $13, the low end of the range of $13 to $15. The company offered 0.5 million more shares than anticipated. Rallybio is currently...read more
Updated Monday, 7/26. After another week of record activity, the IPO market is expected to remain hot with 25 IPOs scheduled for the week ahead. If all scheduled IPOs begin trading as expected, it would be the busiest week for the US IPO market in...read more
Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday. The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of...read more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Rare disease biotech Rallybio prices IPO at $13 low end
Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, raised $81 million by offering 6.2 million shares at $13, the low end of the range of $13 to $15. The company offered 0.5 million more shares than anticipated. Rallybio is currently...read more
US IPO Week Ahead: Robinhood’s billion-dollar deal headlines a 25 IPO week
Updated Monday, 7/26. After another week of record activity, the IPO market is expected to remain hot with 25 IPOs scheduled for the week ahead. If all scheduled IPOs begin trading as expected, it would be the busiest week for the US IPO market in...read more
Rare disease biotech Rallybio sets terms for $81 million IPO
Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday. The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of...read more